文献速递肿瘤 PET/CT放射性药物与辐射防护

PSMA PET/CT联合MRI在前列腺癌局灶治疗筛选中的补充价值:全mount病理验证研究

Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study.
PubMed 文献 · J Nucl Med · 2026-10-29

本研究以全mount病理为金标准,回顾性分析112例接受前列腺癌根治术的患者,评估PSMA PET/CT、多参数MRI(mpMRI)及其联合判断局灶治疗合格性的准确性。结果显示联合成像将敏感性从PET的53%和MRI的70%提高至83%,但特异性降至26%,仍遗漏相当比例的不良病理,提示影像 alone 不应决定治疗资格。

要点

  • 联合PSMA PET/CT与mpMRI可提高排除不良病理特征的敏感性至83%。
  • 联合成像特异性仅26%,仍遗漏部分不良病理,不能单独用于筛选。
  • mpMRI对包膜外侵犯更敏感,PSMA PET/CT特异性更高。

核心结论

  • 联合PSMA PET/CT与mpMRI显著提高排除不良病理特征的敏感性,体现分子与解剖信息的互补,但仍遗漏相当比例不良病理,影像 alone 不应决定局灶治疗资格。

研究设计与样本

  • 回顾性分析UCLA 2017-2024年接受根治性前列腺切除术、术前有PSMA PET/CT和mpMRI、活检Grade Group≤3、单侧病变且PSA<20 ng/mL的患者。
  • 每种模态由两名盲法读者评估包膜外侵犯、精囊侵犯、双侧病变和多灶性,第三名读者裁决分歧;以全mount病理为参考标准比较各模态。

主要发现

  • 112例患者中77例(69%)在全mount病理上不符合局灶治疗条件,包括19例(17%)根治标本存在Grade Group>3病灶。
  • PET的敏感性和特异性分别为53%和54%,mpMRI分别为70%和49%。
  • 联合成像敏感性提高至83%(vs PET P<0.001;vs MRI P=0.002),但特异性降至26%。
  • 在此患病率下每100例患者,联合成像可正确识别约9例额外不合格患者,同时错误排除约7例真正合格者。
  • mpMRI对包膜外侵犯的敏感性高于PET(77% vs 32%,P<0.001),而PET特异性更高(90% vs 58%,P<0.001);联合成像较MRI alone 提高多灶性(44% vs 23%,P=0.001)和双侧病变(45% vs 23%,P=0.002)的检出。

关键数值与推荐

  • 局灶治疗合格需满足:无包膜外侵犯、无精囊侵犯、无双侧病变、无多灶性。
  • 全mount病理不合格定义为:包膜外侵犯、精囊侵犯、多灶或双侧病变且对侧或次要结节Grade Group≥2、或根治标本任何Grade Group>3病灶。

临床怎么用

  • 联合PSMA PET/CT与mpMRI可提高排除不良病理的敏感性,但特异性低,不能单独依据影像决定局灶治疗资格。
  • 临床筛选局灶治疗候选人时,应结合影像、活检病理及其他临床参数综合判断。

局限性

  • 回顾性单中心研究,样本量112例,结论需外部验证。
  • 联合成像特异性仅26%,错误排除约7例真正合格者/100例,可能限制其作为筛选工具的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incremental value of prostate-specific membrane antigen (PSMA) PET/CT over multiparametric MRI (mpMRI) for selecting patients for prostate cancer focal therapy is undefined. Unlike lesion-detection studies, we evaluated whether PSMA PET/CT, mpMRI, and their combination correctly determine focal therapy eligibility when validated against whole-mount histopathology (WMHP). Methods: We retrospectively analyzed patients undergoing radical prostatectomy (RP) at UCLA (2017-2024) with preoperative PSMA PET/CT and mpMRI, a biopsy grade group (GG) of 3 or less, unilateral disease, and a prostate-specific antigen level of less than 20 ng/mL. Two blinded readers per modality assessed extraprostatic extension (EPE), seminal vesicle invasion (SVI), bilateral disease, and multifocality; a third adjudicated discordances. Eligibility required the absence of all 4. On WMHP, ineligibility was EPE, SVI, multifocal or bilateral disease with a contralateral or secondary GG of at least 2 nodules, or any GG greater than 3 focus at RP. Modalities were compared by McNemar tests. Results: Of 112 patients, 77 (69%) were ineligible on WMHP, including 19 (17%) with a GG greater than 3 focus at RP. Sensitivity and specificity were 53% and 54% for PET and 70% and 49% for mpMRI. Combined imaging improved sensitivity to 83% (P < 0.001 vs. PET; P = 0.002 vs. MRI) but reduced specificity to 26%. Per 100 patients at this prevalence, this would correctly identify approximately 9 additional ineligible patients while falsely excluding approximately 7 true candidates. mpMRI was more sensitive than PET for EPE (77% vs. 32%, P < 0.001), whereas PET was more specific (90% vs. 58%, P < 0.001). Combined imaging improved detection of multifocal (44% vs. 23%, P = 0.001) and bilateral disease (45% vs. 23%, P = 0.002) versus MRI alone. Conclusion: Adding PSMA PET/CT to mpMRI significantly improves sensitivity for exclusionary features, reflecting complementary molecular and anatomic information. However, combined imaging still misses a substantial proportion of adverse pathology, so imaging alone should not determine eligibility.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sonni I, Mohammadigoldar Z, Furey G, et al. Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study. J Nucl Med. 2026. PMID: 42957199. doi:10.2967/jnumed.126.273367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。